Literature DB >> 33223766

Molecular interaction analysis of Sulawesi propolis compounds with SARS-CoV-2 main protease as preliminary study for COVID-19 drug discovery.

Muhamad Sahlan1, Rafidha Irdiani1, Darin Flamandita1, Reza Aditama2, Saleh Alfarraj3, Mohammad Javed Ansari4, Apriliana Cahya Khayrani1, Diah Kartika Pratami5, Kenny Lischer1.   

Abstract

Coronavirus disease 2019 (COVID-19), a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global health concern, as the World Health Organization declared this outbreak to be a global pandemic in March 2020. The need for an effective treatment is urgent because the development of an effective vaccine may take years given the complexity of the virus and its rapid mutation. One promising treatment target for COVID-19 is SARS-CoV-2 main protease. Thus, this study was aimed to examine whether Sulawesi propolis compounds produced by Tetragonula sapiens inhibit the enzymatic activity of SARS-CoV-2 main protease. In this study, molecular docking was performed to analyze the interaction profiles of propolis compounds with SARS-CoV-2 main protease. The results illustrated that two compounds, namely glyasperin A and broussoflavonol F, are potential drug candidates for COVID-19 based on their binding affinity of -7.8 kcal/mol and their ability to interact with His41 and Cys145 as catalytic sites. Both compounds also displayed favorable interaction profiles with SARS-CoV-2 main protease with binding similarities compared to inhibitor 13b as positive control 63% and 75% respectively.
© 2020 The Authors.

Entities:  

Keywords:  COVID-19; Molecular docking; Potent inhibitor; SARS-CoV-2 main protease; Sulawesi propolis

Year:  2020        PMID: 33223766      PMCID: PMC7670966          DOI: 10.1016/j.jksus.2020.101234

Source DB:  PubMed          Journal:  J King Saud Univ Sci        ISSN: 1018-3647


Introduction

Coronavirus disease 2019 (COVID-19), is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently considered a global health emergency. Since first being identified in Wuhan, China in December 2019, SARS-CoV-2 has spread widely and infected millions of people globally. On March 11, 2020, the World Health Organization (WHO) declared this outbreak to be a global pandemic. To date, there have been around 1.24 million deaths reported according to WHO as of November 7th, 2020 (World Health Organization, 2020) (Table 1 ).
Table 1

Identified Sulawesi propolis compounds.

NoCompoundMolecular Formula2-Dimensional StructureReferences
1α-Tocopherol succinateC32H52O5(Sahlan et al., 2019)
2XanthoxyletinC15H14O4(Sahlan et al., 2019)
3P-Coumaric acidC9H10O3(Mahadewi et al., 2018)
4CurcumeneC15H22(Mahadewi et al., 2018)
5ThymolC10H14O(Mahadewi et al., 2018)
6TetralinC10H12(Mahadewi et al., 2018)
7DeoxypodophyllotoxinC22H22O7(Sahlan et al., 2019)
8Sulabiroins AC22H22O7(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
9Sulabiroins BC23H26O7(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
102′,3′-Dihydro-3′-hydroxypapuanic acidC25H38O7(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
11(–)-Papuanic acidC25H36O6(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
12(–)-Isocalolongic AcidC24H34O6(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
13Isopapuanic acidC25H36O6(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
14Isocalopolyanic acidC24H32O6(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
15Glyasperin AC25H26O7(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
16Broussoflavonol FC25H26O7(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
17(2S)-5,7-Dihydroxy-4′-methoxy-8-prenylflavanoneC20H20O5(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
18IsorhamnetinC16H12O7(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
19(1′S)-2-Trans,4-trans-abscisic acidC15H20O4(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
20(1′S)-2-Cis,4-trans-abscisic acidC15H20O4(Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b)
Identified Sulawesi propolis compounds. SARS-CoV-2 is a single-stranded ribonucleic acid (RNA) enveloped virus from the genus Betacoronavirus, subfamily Orthocoronavirinae, and family Coronaviridae (Zheng, 2020). Two other viruses belong to this genus, namely Middle East respiratory syndrome virus and severe acute respiratory syndrome virus (SARS-CoV). SARS-CoV-2 was identified to have 82% RNA identity with SARS-CoV (Zhang et al., 2020). Both SARS-CoV and SARS-CoV-2 recognize the same receptor in the human body, namely angiotensin-converting enzyme 2. The SARS-CoV-2 genome encodes a trimeric structural spike protein, a homodimeric cysteine proteinase, an RNA polymerase, and several nonstructural proteins (Calligari et al., 2020). The viral pathogenesis causes several symptoms, such as sore throat, running nose, cough, fever, and eventually respiratory failure. Currently, there is no specific therapy with curative efficacy against the disease (Centers for Disease Control and Prevention, 2020). Several drugs, such as hydroxychloroquine and chloroquine, have been suggested as treatments. However, no studies were adequately powered to prove their efficacy (Pastick et al., 2020). In addition, several reports of serious arrhythmia have been described in patients with COVID-19 who received these compounds (United States Food and Drug Administration, 2020). In addition, efforts are underway to develop vaccines to control the outbreak. However, given the complexity of the virus and the rapid mutation of its single stranded RNA, it may take years to generate effective vaccines (Huanget al., 2020). Thereby, other compounds should be examined to identify an effective treatment with few or no adverse effects. According to Marcucci, propolis, a resinous bee product, exhibits antiviral activity based on the presence of flavonoids, caffeic acid, and esters of aromatic acids (Marcucci, 1995). The antiviral activities of these compounds occur through the inhibition of viral transmission to other cells, inhibition of viral propagation, and destruction of the outer envelope of the virus (Marcucci, 1995). Various experiments have been conducted to analyze the antiviral activities of the compounds. Research by Yildirim et al. revealed that propolis significantly decreased the number of copies of herpes simplex virus 2 after 48 h of incubation (Yildirim et al., 2016). In addition, Gekker et al. demonstrated that propolis has a destructive effect on the outer envelope of human immunodeficiency virus (Gekker et al., 2005). In terms of antiviral activity in the respiratory tract, another study reported that some propolis compounds have lower IC50 values against human rhinovirus than ribavirin (Kwon et al., 2020). The potency of propolis as COVID-19 drug has also been observed through some research. Vardhan and Sahoo (2020) have shown that three propolis components, namely limonin, quercetin and kaempferol have inhibitory potential by binding to viral RNA-dependent RNA polymerase (RdRp) with binding energy −9 to −7.1 kcal/mol through molecular docking study (Vardhan and Sahoo, 2020). Molecular docking enables the virtual screening of millions of compounds in a time- and cost-efficient manner (Pinzi and Rastelli, 2019). Hence, this method is widely used as a preliminary study in drug discovery (Meng et al., 2011). Another molecular docking study by Güler et al. (2020) concluded that identified compounds from alcoholic extract of propolis are able to bind with angiotensin-converting enzyme (ACE)-2. Thus, the compounds may be potential to prevent SARS-CoV-2 to bind with ACE-2 (Güler et al., 2020). Based on these findings, propolis compounds may have potency for treating COVID-19. Further research is needed to evaluate the ability of propolis compounds to inhibit SARS-CoV-2 replication. Other protein in SARS-CoV-2 that is also considered a potential therapeutic target is main protease (Anand et al., 2003). The enzyme cleaves polyproteins translated from viral RNA into 12 smaller proteins that participate in viral replication (Chen et al., 2020). Therefore, viral replication can be blocked by inhibiting this enzyme (Zhang et al., 2020). Previously, Zhang et al. developed peptidomimetic α-ketoamides as potential broad-spectrum inhibitors of main protease in Betacoronaviruses and Alphacoronaviruses (Zhang et al., 2020). One such compound, tert-butyl(1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)-amino)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydro-pyridin-3-yl) carbamate, also known as 13b, inhibited SARS-CoV-2 replication in human Calu3 lung cells. The crystal structure of SARS-CoV-2 main protease in complex with inhibitor 13b is available. Propolis compounds are diverse according to the region (Alday et al., 2016). Beforehand, Sulawesi propolis compounds from North Luwu have been identified by several research (Mahadewi et al., 2018, Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b, Sahlan et al., 2019). Sulawesi propolis previously was known to be produced by Tetragonula aff. biroi. However, recent study rectified that it is actually produced by Tetragonula sapiens (Sayusti et al., 2020). Some research has also proved the health benefits of Sulawesi propolis. Sulawesi propolis exhibits antifungal activity to Candida albicans, C. tropicalis, C. krusei, C. parapsilosis, C. glabrata and Cryptococcus neoformans (Sahlan et al., 2020). Other study showed that Sulawesi propolis is potential to be developed as a non-steroid anti-inflammatory drug and antioxidant agent (Christina et al., 2018, Sahlan et al., 2019). These facts encourage us to do more investigations regarding the health benefits of Sulawesi propolis. The components of antioxidant and flavonoid in Sulawesi propolis may perform antiviral activity. Up to date, there has been no research that aims to evaluate the potency of Sulawesi propolis compounds to treat COVID-19. In this research, molecular docking was performed to analyze the molecular interaction between SARS-CoV-2 main protease (PDB ID: 6Y2F) and Sulawesi propolis compounds. Molecular docking aims to predict the conformation of the ligand within the receptor and assess the binding affinity (Guedes et al., 2014), which is represented by the docking score (kcal/mol). The docking score and binding characteristics of inhibitor 13b were used to judge whether the propolis compounds are potential inhibitors of SARS-CoV-2 main protease. Furthermore, this research also performed molecular docking between SARS-CoV-2 main protease and 14b, a modified version of inhibitor 13b. 14b does not feature a Boc group, which predicted to protect the compound as it crosses the cellular membrane (Zhang et al., 2020). Although 14b was mostly inactive in human Calu3 lung cells, this compound may have lower affinity for plasma proteins than inhibitor 13b (Zhang et al., 2020).

Materials and methods

Hardware and software

Molecular docking was performed using an Asus laptop with an Intel® Core™ i7-8550U @1.80 GHz processor, 8 GB of RAM, the Windows 10 Home Single Language 64-bit operating system, and an Intel® UHD Graphics 620 graphics processing unit. The software used in the study included MarvinSketch (ChemAxon, Budapest, Hungary), Autodock Tools 1.5.6 (The Scripps Research Institute, USA), Autodock Vina (The Scripps Research Institute), LigPlot+ (EMBL-EBI, UK) and Visual Molecular Dynamics (University of Illinois, Urbana-Champaign).

Lipinski’s rule of five (RO5) selection

First, 20 identified Sulawesi propolis compounds from North Luwu, South Sulawesi, Indonesia were selected based on Lipinski’s RO5. The rules aim to assess the solubility and permeability of drug candidates. The RO5 stated that poor absorption or permeability are more likely to occur when a compound has molecular weight greater than 500 g/mol, Log P greater than 5, H-bond donors more than 5 and H-bond acceptors more than 10 (Lipinski et al., 1997). Sulawesi propolis compounds that violates more than 2 rules were thrown away. Lipinski’s RO5 was assessed by using MarvinSketch (ChemAxon, 2018).

Protein preparation

The SARS-CoV-2 main protease in complex with the α-ketoamide 13b (PDB ID: 6Y2F) was obtained from the Protein Data Bank (http://www.rcsb.org) in the.pdb format (Zhang et al., 2020). The Protein Data Bank is an open access digital data resource that provides 3D structure data for large biological molecules (Berman et al., 2013). The protein and inhibitor 13b file was then separated into two different.pdb files using Visual Molecular Dynamics (Humphrey et al., 1996). Then, the separated protein files were loaded into Autodock Tools 1.5.6 for further preparation consisting of the addition of polar hydrogens, addition of kollman charges and conversion of the file to the .pdbqt format (Forli et al., 2016) for compatibility for docking using Autodock Vina.

Ligands preparation

Meanwhile, the test ligands were selected Sulawesi propolis compounds from North Luwu produced by Tetragonula sapiens and 14b using inhibitor 13b as control. The structure of inhibitor 13b and 14b are shown in Fig. 1 . Excluding inhibitor 13b, the 2D structures of the ligands were constructed and converted into 3D structures in the .pdb format using MarvinSketch. Then, the ligands were loaded to Autodock Tools 1.5.6 to add polar hydrogens as well as gasteiger charges, and convert the file to the.pdbqt format.
Fig. 1

Structure of inhibitor 13b and 14b (Zhang et al., 2020).

Structure of inhibitor 13b and 14b (Zhang et al., 2020).

Parameter optimization

Before performing molecular docking between propolis compounds and main protease, the optimal specific search space was determined. The search space is the area within the protein in which the docking simulation will be performed. It may represent the locations of the binding sites. The optimal search space can be predicted via docking between the native ligand of the protein structure, in this case 13b, using the protein that was separated in the protein preparation step. This method is also known as “redocking.” Redocking and the subsequent docking simulation were performed using Autodock Vina. In terms of accuracy, Autodock Vina offers more accurate binding mode predictions than Autodock Tools (Vieira and Sousa, 2019). Adjustment was performed for three parameters to obtain the optimal specific search space, namely the center of the grid box, number of points in the x, y, and z dimensions, and grid spacing. Based on the redocking simulation, it was found that the binding site had a higher probability to be located at the following coordinates: x  = 11.476, y = −1.396, and z = 20.745. The number of points in the x, y, and z dimensions were all set to 25 Å, and the grid spacing was adjusted to 1.0 Å. After the docking score was obtained, the root mean square deviation (RMSD) of the first rank ligand pose was evaluated. An RMSD of less than 2.0 Å indicates that the redocking procedure is accurate (Ramírez and Caballero, 2018). Thereby, the docking coordinates could be used to dock the propolis compounds onto the protein.

Molecular docking analysis of propolis compounds onto main protease

To identify which propolis compounds are potential SARS-CoV-2 inhibitors, the compounds were docked into the protein individually using the coordinates and grid parameters obtained from the redocking simulation. The simulations were performed using Autodock Vina with exhaustiveness value set to 64. After the docking score for each compound was obtained, the interactions between the protein and the ligands with the lowest docking scores were analyzed using Ligplot+, which provides 2D visualization of molecular interactions.

Results and discussion

This research analyzed the molecular interactions between selected Sulawesi propolis compounds produced by Tetragonula sapiens and SARS-CoV-2 main protease in an effort to identify potential inhibitors. Main protease was selected because of its important role in viral replication. Several main protease structures were available in the Protein Data Bank. Of these, PDB ID 6Y2F was selected because it featured inhibitor 13b bound to the protein. Inhibitor 13b was previously proven to reduce SARS-CoV-2 RNA levels in infected human lung cells with an IC50 of 0.67 ± 0.18 μm (Zhang et al., 2020).

Lipinski’s RO5 selection result

First of all, 19 Sulawesi propolis compounds from North Luwu were selected based on Lipinski’s RO5 in Table 2 . According to the result, (-)-papuanic acid, isopapuanic acid, isocalopolyanic acid and curcumene have Log P of greater than 5.0. In the meantime, a compound, namely α-tocopherol succinate, violates two out of four rules, which are molecular weight and log P parameter. A molecular weight greater than 500 g/mol will lead to poor permeability when a drug molecule penetrates biological membrane through passive diffusion process (Qiu et al., 2016). Meanwhile, Log P represents octanolwater partition coefficient. A drug molecule with high Log P value tends to be more nonpolar and have poorer aqueous permeability (Templeton et al., 2015). Although there are several violations, the number of rules being obeyed is sufficient to indicate that the compounds have good permeability. In addition, there are some tolerable Lipinski’s RO5 parameter value for natural compounds.
Table 2

Lipinski’s RO5 selection.

No.CompoundsMolecular weight (g/mol)Log PNumber of H-bond acceptorNumber of H-bond donorNumber of violations
1Sulabiroins A398.4112.74700
2Sulabiroins B414.4542.55700
32',3'-Dihydro-3'-hydroxypapuanic acid450.5724.33730
4(−)-Papuanic acid432.5575.57621
5(−)-Isocalolongic acid404.5034.78620
6Isopapuanic acid432.5575.57621
7Isocalopolyanic acid416.5145.03621
8Glyasperin A438.4764.84750
9Broussoflavonol F438.4764.84750
10(2s)-5,7-Dihydroxy-4'-methoxy-8-prenylflavanone340.3754.19530
11Isorhamnetin316.2651.78740
12(1's)-2-Trans,4 trans-abscisic acid264.3212.08420
13(1's)-2-Cis,4 trans-abscisic acid264.3212.08420
14α-tocopherol succinate530.7909.18412
15Xanthoxyletin258.2732.01300
16P-coumaric acid164.1602.12320
17Curcumene202.3415.19001
18Thymol150.2213.42110
19Tetralin132.2063.27000
20Deoxypodophyllotoxin398.4112.63600
Lipinski’s RO5 selection.

Docking score

Selected Sulawesi propolis compounds, inhibitor 13b and 14b then were docked to main protease by using Autodock Vina. Docking simulation by using Autodock Vina produces two results, which are the most stable ligand poses and docking score. The docking score is generated from an empirical calculation that considers the number of hydrophobic interactions and hydrogen bonding (Trott and Olson, 2010). The greater the number of interactions, the greater the tendency for the docking score to be negative. The docking score may become a representative of binding affinity, and it is inversely proportional to the binding stability (Flamandita et al., 2020). The negative docking score indicates that the compound, which in this case acts as a ligand, has the ability to interact with the protein. Meanwhile, the most stable ligand pose will further be used to find out which amino acid residues in the protein interact with the ligand. Thereafter this is referred as interaction profile. By comparing interaction profile between SARS-CoV-2 main protease and propolis compounds with SARS-CoV-2 main protease and inhibitor 13b, the potency of propolis compounds to have the ability to inhibit the protein with the same pathway as inhibitor 13b may be evaluated. The docking score between main protease and test compounds are available in Table 3 . Based on the docking simulation, 13b and 14b bound to main protease with a binding affinity of −8.2 and −7.2 kcal/mol. Meanwhile, among the propolis compounds, the three lowest docking scores were obtained for broussoflavonol F, glyasperin A, and sulabiroins A, with values of −7.8, −7.8, and −7.6 kcal/mol, respectively. Broussoflavonol F and glyasperin A are identified as flavonoids, while sulabiroins A is a derivative of podophyllotoxin compounds (Miyata et al., 2019, Miyata et al., 2020a, Miyata et al., 2020b). The interaction profiles of these three compounds, inhibitor 13b and 14b with main protease severally then were analyzed.
Table 3

Docking score between main protease and test compounds.

NoCompoundsDocking score (kcal/mol)
1* Inhibitor 13b−8.2
214b−7.2
3Broussoflavonol F−7.8
4Glyasperin A−7.8
5Sulabiroins A−7.6
6Isorhamnetin−7.5
7Deoxypodophyllotoxin−7.3
8(2S)-5,7-Dihydroxy-4′-methoxy-8-prenylflavanone−7.1
9Sulabiroins B−7.0
10Isocalopolyanic acid−6.8
11Isopapuanic acid−6.8
122′,3′-Dihydro-3′-hydroxypapuanic acid−6.7
13(−)-Isocalolongic acid−6.7
14(−)-Papuanic acid−6.6
15Xanthoxyletin−6.2
16(1′S)-2-Trans-4-trans-abscisic acid−6.1
17(1′S)-2-Cis-4-trans-abscisic acid−5.9
18α-Tocopherol succinate−5.1
19P-Coumaric acid−4.9
20Curcumene−4.7
21Thymol−4.7
22Tetralin−4.4

*) Native ligand as a control.

Docking score between main protease and test compounds. *) Native ligand as a control.

Interaction profile

The interaction profile analysis was focused on the existence of interaction with His41 and Cys145. These amino acids have an important role as main protease catalytic sites. Thus, propolis compounds must interact with these sites in order to inhibit the activity of the enzyme. The two-dimensional (2D) visualization of the interaction of main protease with 13b, broussoflavonol F, glyasperin A, and sulabiroins A were presented in Fig. 2 . The interaction profile between main protease and inhibitor 13b and 14b were firstly analyzed. According to the visualization, the docking simulation successfully captured the interaction of inhibitor 13b with both His41 and Cys145, in line with the results reported by Zhang et al. (2020) as the crystallographer (Zhang et al., 2020). The shortest interatomic distance between main protease with His41 and Cys145 are 3.03 and 3.27 Å respectively. In the meantime, 14b only interacts hydrophobically with His41. Based on this finding, although 14b may have a better in vivo potency due to lower affinity for plasma protein binding, it does not have favorable interaction towards the main protease.
Fig. 2

Visualization of the molecular interactions of main protease with various ligands. (a) 13b, (b) 14b, (c) broussoflavonol F, (d) glyasperin A, (e) sulabiroins A. The purple lines denote the ligand structure, whereas the brown lines denote the structure of amino acid residues. The molecular interactions are reflected as dashed lines and arcs. The green dashed lines between atoms represent hydrogen bonds, and the numbers above these lines indicate the length of the bond. Meanwhile, the arcs with spokes radiating toward the ligand atoms represent hydrophobic interactions. The atoms involve in hydrophobic interactions are indicated by the presence of spokes radiating back (Wallace et al., 1995).

Visualization of the molecular interactions of main protease with various ligands. (a) 13b, (b) 14b, (c) broussoflavonol F, (d) glyasperin A, (e) sulabiroins A. The purple lines denote the ligand structure, whereas the brown lines denote the structure of amino acid residues. The molecular interactions are reflected as dashed lines and arcs. The green dashed lines between atoms represent hydrogen bonds, and the numbers above these lines indicate the length of the bond. Meanwhile, the arcs with spokes radiating toward the ligand atoms represent hydrophobic interactions. The atoms involve in hydrophobic interactions are indicated by the presence of spokes radiating back (Wallace et al., 1995). The interaction profile between main protease and each propolis compounds were then analyzed. Based on the results, broussoflavonol F forms hydrogen bond with Cys145 and interacts hydrophobically with His41. The interatomic distance between main protease and Cys145 is 3.27 Å. The same value of interatomic distance compared to inhibitor 13b shows that broussoflavonol F may bind to Cys145 as strong as inhibitor 13b. Meanwhile, glyasperin A does not form hydrogen bonds with any catalytic sites. It interacts hydrophobically with both catalytic sites instead. Hydrophobic interaction with the catalytic sites shows that although the binding affinity between the compound and the protein may not as strong as in hydrogen bonds, the compound may still have the potency to inhibit the activity of the enzyme. Lastly, for sulabiroins A, it is shown that this compound only interacts hydrophobically with one catalytic site, which is His41. For further consideration, binding similarity between interaction profile of main protease with the three propolis compounds and 14b compared to interaction profile of main protease and inhibitor 13b were calculated. Based on the calculation, 14b, broussoflavonol F, glyasperin A and sulabiroins A bound to main protease with the similarity of 71%, 75%, 63% and 44% respectively. The summary of interaction profile between main protease and each test compounds are available in Table 4 , while Table 5 summarizes the hydrogen bonds present between main protease and each test compounds.
Table 4

Interaction profiles between main protease and test compounds

No.CompoundsHydrogen bondsHydrophobic interactionsNumber of interactionsBinding similarity
1* 13bHis41, Gly143, Ser144, Cys145, Glu166Thr25, Cys44, Met49, Leu141, Asn142, His163, His164, Met165, Leu167, Asp187, Gln18916100%
214bPhe140, Glu166His41, Met49, Leu141, Asn142, His163, His164, Met165, Leu167, Pro168, Asp187, Arg188, Gln1891471%
3Broussoflavonol FGly143, Ser144, Cys145Thr26, His41, Met49, Leu141, Asn142, His163, His164, Met165, Glu166, Arg188, Gln1891475%
4Glyasperin AThr25, His164, Arg188His41, Cys145, Met165, Glu166, Val186, Asp187, Gln189, Thr190, Gln1921363%
5Sulabiroins AGlu166His41, Asn142, His164, Met165, Asp187, Arg188, Gln189844%

*) Native ligand as a control.

Table 5

Hydrogen bonds between main protease and test compounds

No.CompoundsHydrogen bond distance (Å)Interacting amino acidBinding ligand groupBinding amino acid group
1* 13b2,80Glu166–NH–O
2,86Ser144–NH–OH
3,03His41–O–NH
3,12Gly143–O–NH2
3,15Ser144–O–NH2
3,20Gly143–O–NH2
3,27Cys145–O–NH2
3,30Glu166–O–NH2
3,32Cys145–O–SH
214b3.02Phe140–NH2–O
3.20Glu166–O–NH2
3Broussoflavonol F2.94Ser144–OH–O
2.97Ser144–OH–NH2
3.01Gly143–OH–NH2
3.27Cys145–OH–NH2
4Glyasperin A2.73Thr25–OH–OH
2.73Arg188–OH–OH
2.99His164–OH–O
3.01Arg188–OH–NH2
5Sulabiroins A3.06Glu166–O–NH2

*) Native ligand as a control.

Interaction profiles between main protease and test compounds *) Native ligand as a control. Hydrogen bonds between main protease and test compounds *) Native ligand as a control.

Conclusion

Sulawesi propolis compounds from North Luwu that are produced by Tetragonula sapiens exhibit potential to inhibit SARS-CoV-2 main protease activity. Three compounds, namely broussoflavonol F, glyasperin A, and sulabiroins A, displayed the greatest docking score, with values of −7.8, −7.8, and −7.6 kcal/mol, respectively. The study results suggest that molecular dynamic simulation should be conducted for broussoflavonol F and glyasperin A given that both compounds interact with main protease catalytic sites and have the ability to bind with main protease with binding similarity of 75% and 63% respectively compared to potent inhibitor. Further research should be conducted to verify the potency and safety of broussoflavonol F and glyasperin A to the treatment of COVID-19.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper..
  20 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

2.  AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.

Authors:  Oleg Trott; Arthur J Olson
Journal:  J Comput Chem       Date:  2010-01-30       Impact factor: 3.376

3.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

4.  How community has shaped the Protein Data Bank.

Authors:  Helen M Berman; Gerard J Kleywegt; Haruki Nakamura; John L Markley
Journal:  Structure       Date:  2013-09-03       Impact factor: 5.006

5.  Anti-HIV-1 activity of propolis in CD4(+) lymphocyte and microglial cell cultures.

Authors:  Genya Gekker; Shuxian Hu; Marla Spivak; James R Lokensgard; Phillip K Peterson
Journal:  J Ethnopharmacol       Date:  2005-07-19       Impact factor: 4.360

6.  Computational protein-ligand docking and virtual drug screening with the AutoDock suite.

Authors:  Stefano Forli; Ruth Huey; Michael E Pique; Michel F Sanner; David S Goodsell; Arthur J Olson
Journal:  Nat Protoc       Date:  2016-04-14       Impact factor: 13.491

7.  Antiviral Activity of Hatay Propolis Against Replication of Herpes Simplex Virus Type 1 and Type 2.

Authors:  Ayse Yildirim; Gulay Gulbol Duran; Nizami Duran; Kemal Jenedi; Behiye Sezgin Bolgul; Meral Miraloglu; Mustafa Muz
Journal:  Med Sci Monit       Date:  2016-02-09

Review 8.  Molecular Docking: Shifting Paradigms in Drug Discovery.

Authors:  Luca Pinzi; Giulio Rastelli
Journal:  Int J Mol Sci       Date:  2019-09-04       Impact factor: 5.923

9.  Anti-inflammatory activity of Tetragronula species from Indonesia.

Authors:  Muhamad Sahlan; Andrea Devina; Diah Kartika Pratami; Herbert Situmorang; Siti Farida; Abdul Munim; Benyamin Kusumoputro; Masafumi Yohda; Ahmad Faried; Misri Gozan; Mia Ledyawati
Journal:  Saudi J Biol Sci       Date:  2018-12-17       Impact factor: 4.219

10.  Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.

Authors:  Yu Wai Chen; Chin-Pang Bennu Yiu; Kwok-Yin Wong
Journal:  F1000Res       Date:  2020-02-21
View more
  7 in total

Review 1.  Propolis: An update on its chemistry and pharmacological applications.

Authors:  Rajib Hossain; Cristina Quispe; Rasel Ahmed Khan; Abu Saim Mohammad Saikat; Pranta Ray; Damira Ongalbek; Balakyz Yeskaliyeva; Divya Jain; Antonella Smeriglio; Domenico Trombetta; Roghayeh Kiani; Farzad Kobarfard; Naheed Mojgani; Parvaneh Saffarian; Seyed Abdulmajid Ayatollahi; Chandan Sarkar; Mohammad Torequl Islam; Dılhun Keriman; Arserim Uçar; Miquel Martorell; Antoni Sureda; Gianfranco Pintus; Monica Butnariu; Javad Sharifi-Rad; William C Cho
Journal:  Chin Med       Date:  2022-08-26       Impact factor: 4.546

2.  In-vitro antioxidant, in-vivo anti-inflammatory, and acute toxicity study of Indonesian propolis capsule from Tetragonula sapiens.

Authors:  Siti Farida; Diah Kartika Pratami; Muhamad Sahlan; Dian Ratih Laksmitawati; Etin Rohmatin; Herbert Situmorang
Journal:  Saudi J Biol Sci       Date:  2021-12-16       Impact factor: 4.052

3.  Amomum tsao-ko essential oil, a novel anti-COVID-19 Omicron spike protein natural products: A computational study.

Authors:  Ju-Zhao Liu; Hong-Chang Lyu; Yu-Jie Fu; Qi Cui
Journal:  Arab J Chem       Date:  2022-04-18       Impact factor: 6.212

Review 4.  Propolis in Metabolic Syndrome and Its Associated Chronic Diseases: A Narrative Review.

Authors:  Felix Zulhendri; Munir Ravalia; Krishna Kripal; Kavita Chandrasekaran; James Fearnley; Conrad O Perera
Journal:  Antioxidants (Basel)       Date:  2021-02-26

5.  Molecular docking and dynamics studies on propolis sulabiroin-A as a potential inhibitor of SARS-CoV-2.

Authors:  Jaka Fajar Fatriansyah; Raihan Kenji Rizqillah; Muhamad Yusup Yandi; Muhamad Sahlan
Journal:  J King Saud Univ Sci       Date:  2021-11-15

Review 6.  Potential effects of propolis and honey in COVID-19 prevention and treatment: A systematic review of in silico and clinical studies.

Authors:  Witoo Dilokthornsakul; Ramanya Kosiyaporn; Rattanamanee Wuttipongwaragon; Piyameth Dilokthornsakul
Journal:  J Integr Med       Date:  2022-01-31

Review 7.  New Insights into Potential Beneficial Effects of Bioactive Compounds of Bee Products in Boosting Immunity to Fight COVID-19 Pandemic: Focus on Zinc and Polyphenols.

Authors:  Meryem Bakour; Hassan Laaroussi; Driss Ousaaid; Asmae El Ghouizi; Imane Es-Safi; Hamza Mechchate; Badiaa Lyoussi
Journal:  Nutrients       Date:  2022-02-23       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.